Pfizer’s Second Gut Punch Shows Pitfalls of Weight-Loss Pills
Bloomberg Businessweek
Introduction
A discussion on Pfizer's decision to drop the development of a twice daily version of its obesity pill and the challenges of developing a weight loss drug, with insights from a Bloomberg News Health reporter.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
